The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

Preeclampsia Clinical Trial

Official title: The Role and Mechanism of GPER Hippo Pathway in Regulating Uterine Arterial Smooth Muscle CBS/H2S in the Pathogenesis of Preeclampsia

Status Enrolling by invitation

Clinical Trial Summary

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

• The pathological significance of GPER in uterine artery dilation in preeclampsia

• The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Clinical Trial Description

1. Measure the content of H2S in uterine arterial smooth muscle and circulation of normal pregnancy and PE pregnant women, and analyze the relationship between the content of H2S in uterine arterial smooth muscle and circulation of PE pregnant women and PE.

2. Knock down the GPER and overexpression of GPER in HTR-8 cells, and detect the expression of GPER, CBS, and Hippo pathway related proteins using Western blot and qRT-PCR to verify the efficiency of knockdown and overexpression. Use different concentrations of H2S donor (GYY4137) to interfere with HTR-8 cells after treatment, and use RT-PCR and Western blot to detect the mRNA and protein expression of downstream molecules YAP and TAZ in Hippo pathway in cells, respectively. ;

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

• NCT number: NCT06205771
• Study type: Interventional
• Source: Qianfoshan Hospital
• Status: Enrolling by invitation
• Phase: N/A
• Start date: April 10, 2024
• Completion date: December 2029